- Original article
- Open Access
Incidence and mortality of liver cancer in China in 2011
© Zuo et al. 2015
- Received: 25 June 2015
- Accepted: 7 September 2015
- Published: 15 October 2015
Liver cancer is a common cancer with poor prognosis in China. In this study, the national population-based cancer registration data were used to evaluate and analyze liver cancer incidence and mortality in China in 2011 and provide a reference for liver cancer prevention and control.
We collected and evaluated the incidence and mortality data of liver cancer in 2011 from 177 cancer registries with qualified data. These data were used in the final analysis including calculating crude, standardized, and truncated incidences and mortalities, and estimated new liver cancer cases and deaths using age-specific rates and the corresponding populations. The national census in 2000 and Segi’s population were used for age-standardized rates.
The estimates of new liver cancer cases and deaths were 355,595 and 322,416, respectively, in China in 2011. The crude incidence, age-standardized rate of incidence by Chinese standard population (ASRIC), and age-standardized rate of incidence by world standard population (ASRIW) of liver cancer were 26.39/100,000, 19.48/100,000, and 19.10/100,000, respectively; the crude mortality, age-standardized rate of mortality by Chinese standard population (ASRMC), and age-standardized rate of mortality by world standard population (ASRMW) of liver cancer were 23.93/100,000,17.48/100,000, and 17.17/100,000, respectively. The incidence and mortality were higher in rural areas than in urban areas and higher in males than in females. The age-specific incidence and mortality of liver cancer increased greatly with age, particularly after 30 years and peaked at 80–84 or 85+ years.
Liver cancer is a common cancer in China, particularly for males and residents in rural areas. Targeted prevention, early detection, and treatment programs should be carried out.
- Liver cancer
Liver cancer is one of the most common malignant tumors worldwide. According to GLOBOCAN 2012, it was estimated that 782,000 people were diagnosed with liver cancer and that 746,000 people died of this disease, accounting for 5.6% of all new cancer cases and 9.1% of all cancer deaths worldwide, making liver cancer the sixth most common type of cancer and the second leading cause of cancer-related death; moreover, more than 50% of the incident and death cases occurred in China . According to the estimation of the National Central Cancer Registry (NCCR) of China, the liver cancer incidence and mortality were 27.29/100,000 and 23.76/100,000, respectively, making it the fourth most common cancer and the second leading cause of death in 2010 . NCCR is responsible for cancer data collection, evaluation, and publication in China. In 2014, NCCR collected the incidence and mortality data of liver cancer for the calendar year of 2011 from 234 cancer registries. Qualified data from 177 registries were accepted to analyze the incidence and mortality status of liver cancer across the country and in different areas to provide a reference for liver cancer prevention and control.
The incidence and death data of liver cancer in 2011 were retrieved from the National Cancer Registry Database held by the NCCR of China. The criteria for data quality were as follows: the percentage of cases morphologically verified (MV%) was higher than 66%, the percentage of death certificate-only cases (DCO%) was lower than 15%, the mortality to incidence (M/I) ratio was between 0.6 and 0.8, and the percentage of the diagnosis of unknown basis (UB%) was lower than 5%. The registries were stratified into grades A, B, C, and D according to the above criteria for data quality. Among all registries, grades A and B registries were included in the annual report, and grade C registries, with only individual indices that failed to reach the criteria of grade B, were also included as a particular reason; grade D registries were excluded. The 177 qualified registries were located in 28 provinces, autonomous regions, and municipalities directly under the central government: 77 in urban areas and 100 in rural areas. The population data came from the Bureaus of Statistics or Public Security at cancer registration areas. The 177 registries covered 175,310,169 people (88,655,668 males and 86,654,501 females) and accounted for 13.01% of the national population at the end of 2011: 98,341,507 of them in urban areas accounted for 56.10% of the population covered by the 177 registries, and 76,968,662 in rural areas accounted for 43.90%.
National population estimates
The national population in 2011 was estimated based on the fifth National Population Census data (2000) provided by the National Statistics Bureau of China, considering the changes in the age composition, sex ratio, and proportion of urban and rural transformation released by the National Bureau of Statistics (http://data.stats.gov.cn/). The national population in 2011 was stratified by area (urban and rural), sex (male and female), and age groups (0–, 1–4, 5–84 sub-stratified by 5, and 85+ years). The changes in age-specific death probability were also adjusted when calculating the national population. Linear changes were assumed in each age group between the fifth and sixth Population Censuses.
All liver cancer data coded as C22 in the tenth version of the International Classification of Diseases (ICD-10) were analyzed. Incident and death cases, proportions, and crude, standardized, accumulated, truncated, and age-specific incidences and mortalities were calculated using the methods recommended by the National Cancer Registration Manual . The fifth Chinese National Census of 2000 and Segi’s world population were used for age-standardized rates. The above indices were calculated by region and sex stratifications. Age-specific estimates of new cases and deaths at each stratum were obtained by multiplying the age-specific incidence and mortality with the corresponding populations. The nationwide estimates of new cases and deaths were obtained by pooling the calculations .
Data quality of the liver cancer registration in China in 2011
Estimated liver cancer incidence
Liver cancer incidence in China in 2011
No. of cases
Crude incidence (1/105)
Cumulative rate (%)
Age 0–74 years
Age 35–64 years
Incidence difference between areas
The estimate of new liver cancer cases in urban areas in 2011 was 164,528, accounting for 9.11% of all new cancer cases and making liver cancer the fourth most common cancer in urban areas. The crude incidence, ASRIC, and ASRIW in urban areas were 23.82/100,000, 17.07/100,000, and 16.75/100,000, respectively. The estimate of new liver cancer cases in rural areas in 2011 was 191,067, accounting for 12.20% of all new cancer cases and making liver cancer the fourth most common cancer in rural areas. The crude incidence, ASRIC, and ASRIW in rural areas were 29.10/100,000, 22.20/100,000, and 21.73/100,000, respectively (Table 2). The crude incidence, ASRIC, and ASRIW in rural areas were 1.22, 1.30, and 1.29 times greater than those in urban areas, respectively (Table 2).
Estimated liver cancer mortality
Liver cancer mortality in China in 2011
No. of cases
Crude mortality (1/105)
Age 0–74 years
Age 35–64 years
Mortality difference between areas
Liver cancer deaths in urban areas were estimated at 146,618, accounting for 13.75% of all cancer deaths and making liver cancer the second most common cause of cancer death in urban areas in 2011. The crude mortality, ASRMC, and ASRMW in urban areas were 21.22/100,000, 15.04/100,000, and 14.79/100,000, respectively. Liver cancer deaths in rural areas were estimated at 175,798, accounting for 16.80% of all cancer deaths and making liver cancer the second most common cause of cancer death in rural areas in 2011. The crude mortality, ASRMC, and ASRMW in rural areas were 26.78/100,000, 20.23/100,000, and 19.83/100,000, respectively (Table 3). The mortality was higher in rural areas than in urban areas. The crude mortality, ASRMC, and ASRMW in rural areas were 1.26, 1.34, and 1.34 times greater than those in urban areas, respectively.
Liver cancer is a serious problem in developing regions, where 83% of new cancer cases worldwide occurred in 2012. According to GLOBOCAN 2012, the ASRIW and ASRMW of liver cancer in 2012 were 10.1/100,000 and 9.5/100,000 worldwide, 12.0/100,000 and 11.5/100,000 in developing countries, and 5.4/100,000 and 4.6/100,000 in developed countries, respectively . In the present study, there were 355,595 new liver cancer cases and 322,416 deaths that occurred in 2011, making liver cancer the fourth most common cancer and the second leading cause of cancer-related death in China. The ASRIW and ASRMW of liver cancer in China in 2011 were 19.10/100,000 and 17.17/100,000, respectively; compared with the data of GLOBOCAN in 2012, both the incidence and mortality of liver cancer in China were at high levels worldwide. However, in China, compared with the liver cancer data in 2010 , the crude incidence, ASRIC, and ASRIW in 2011 were lower; the crude mortality in 2011 was similar to that in 2010, and ASRMC and ASRMW in 2011 were lower.
In China, in 2011, both the incidence and mortality of liver cancer in males were significantly higher than those in females. The reasons for the higher rates in males may be related to genetic factors [7, 8] and their high proportion of alcohol consumption, which is a risk factor of liver cancer [9, 10]. Both the incidence and mortality of liver cancer were higher in rural areas than in urban areas. The higher incidence in rural areas is most likely related to their easy access to risk factors, such as aflatoxin exposure, unhealthy diet habits, polluted water, and blood transfusion [11, 12]. Due to the low level of medical treatment and limited medical resources in rural areas, the mortality in rural areas was higher than that in urban areas. From a population-based cancer survival study, the 5-year relative survival rate of liver cancer patients was 10.1% in China, and the survival rate of rural patients was less than half of that of their urban counterparts . The government should enhance the quality of health services, improve the rural medical service level, and balance medical resources between urban and rural areas to bridge the gap. The survival rate of patients with liver cancer was generally low in both developed and developing regions. According to the report from a global surveillance of cancer survival, the 5-year survival rate of liver cancer patients is below 20% everywhere in Europe, in the range of 15%–19% in North America, and as low as 7%–9% in Mongolia and Thailand . The prognosis for patients with liver cancer is very poor, and advances in cancer prevention, early detection, and treatment are the main means to reduce the mortality of liver cancer.
With changes in dietary habits and the implementation of neonatal hepatitis B virus (HBV) vaccination for years, infections by aflatoxin and HBV have been effectively controlled [15, 16]. The trend analyzed from Qidong, Jiangsu showed that the age-standardized rate is decreasing, whereas the crude incidence of liver cancer is still increasing mainly because of population aging . To decrease the incidence and mortality in males and in rural areas, targeted prevention, early detection, and treatment programs should be carried out, enhancing secondary prevention based on strengthening primary prevention.
W-QC and H-MZ conceived of the study and participated in its design and coordination. R-SZ and S-WZ performed the statistical analyses and interpretation. T-TZ drafted the manuscript. All authors read and approved the final manuscript.
We gratefully acknowledged the cooperation of all the population-based cancer registries in providing cancer statistics, data collection, sorting, verification, and database creation.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.View ArticlePubMedGoogle Scholar
- Chen WQ, Zheng RS, Zhang SW, Zhao P, Zeng HM, Zou XN, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26:48–58.PubMed CentralPubMedGoogle Scholar
- National Office for Cancer Control and Prevention, Information Centre of Health Statistics of Health Ministry, National Centre for Cancer Registration. Guideline for cancer registration in China. Beijing: Military Medical Science Press; 2004. p. 50–7 (in Chinese).Google Scholar
- Chen WQ, Zheng RS, Zeng HM, Zhang SW, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12.PubMed CentralView ArticlePubMedGoogle Scholar
- International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2014. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 23 Apr 2015.
- Wei KR, Yu X, Zheng RS, Peng XB, Zhang SW, Ji MF, et al. Incidence and mortality of liver cancer in China, 2010. Chin J Cancer. 2014;33:388–94.PubMed CentralPubMedGoogle Scholar
- Sander LE, Trautwein C, Liedtke C. Is interleukin-6 a gender-specific risk factor for liver cancer? Hepatology. 2007;46:1304–5.View ArticlePubMedGoogle Scholar
- Su CH, Lin Y, Cai L. Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev. 2013;14:4953–60.View ArticlePubMedGoogle Scholar
- Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, Wei WQ, et al. Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev. 2013;14:7251–6.View ArticlePubMedGoogle Scholar
- Lee EY, Xuan Mai TT, Chang Y, Ki M. Trends of liver cancer and its major risk factors in Korea. Epidemiol Health. 2015;37:e2015016.View ArticlePubMedGoogle Scholar
- Fukuda A, Sugimachi K, Tokudome S, Ikeda M, Koga S, Hirohata T. Blood transfusion as a risk factor for cirrhosis and liver cancer: a matched case-control study. J Natl Cancer Inst. 1989;81:1189–90.View ArticlePubMedGoogle Scholar
- Yang BH, Zhang BH. Risk factors and prevention for primary liver cancer. Linchuang Gan Dan Bing Za Zhi. 2012;28:253–5 (in Chinese).Google Scholar
- Zeng HM, Zheng RS, Guo YM, Zhang SW, Zou XN, Wang N, et al. Cancer survival in China, 2003–2005: a population-based study. Int J Cancer. 2015;136:1921–30.View ArticlePubMedGoogle Scholar
- Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977–1010.View ArticlePubMedGoogle Scholar
- Qu CF, Chen TY, Fan CS, Zhan QM, Wang YT, Lu JH, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med. 2014;11:e1001774.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen JG, Egner PA, Ng D, Jacobson LP, Munoz A, Zhu YR, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res. 2013;6:1038–45.View ArticleGoogle Scholar
- Chen JG, Zhu J, Zhang YH, Chen YS, Ding LL. Incidence trend of liver cancer: an analysis of 40 years data from Qidong population-based cancer registry. Zhongguo Zhong Liu. 2014;23:621–8 (in Chinese).Google Scholar